Skip to main content
Premium Trial:

Request an Annual Quote

Joseph Keegan, Winnie Wan, Kevin King, Peter DeComo, John Kuzmishin, John Miclot, Elizabeth Woo, and Edward Machuga

Joseph Keegan has been named president and CEO of ForteBio, effective Sept. 24. Keegan joins the firm from Molecular Devices, where he served as president and CEO until the firm was acquired earlier this year by MDS. Keegan replaces founding CEO Winnie Wan, who will continue to serve on ForteBio’s board of directors.

Affymetrix said this week that Kevin King has been promoted from president of the life sciences business and executive vice president to president of the company. King joined Affy in January from Thomson Healthcare, where he served as president and CEO. He is a former vice president and general manager of global clinical systems for GE Healthcare.

The Pittsburgh Life Sciences Greenhouse has elected several new members to its board of directors. Electees include Peter DeComo, chairman and CEO of Renal Solutions; John Kuzmishin, VP of strategic business initiatives at the University of Pittsburgh Medical Center; John Miclot, president and CEO of Respironics; and Elizabeth Woo, VP of biotechnology for Thermo Fisher Scientific.

Epitome Biosystems has named Edward Machuga VP of sales and marketing. Machuga previously served in sales and marketing roles at GE Healthcare, TekCel, Argonaut Technologies, Applied Biosystems, and Perseptive Biosystems.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.